Review anchor
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A
CHEMBL3012
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats High affinity 3',5'-cyclic-AMP phosphodiesterase 7A as ChEMBL target CHEMBL3012, mapped to UniProt Q13946. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3012
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13946
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why High affinity 3',5'-cyclic-AMP phosphodiesterase 7A matters
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A is reviewed as High affinity 3',5'-cyclic-AMP phosphodiesterase 7A (UniProt Q13946); the current evidence base includes 2 approved drugs, 1016 compounds, and 148 assays, with lead potency reaching pChEMBL 9.5.
Protein context
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A Sequence length is 482 aa.
Review this target as High affinity 3',5'-cyclic-AMP phosphodiesterase 7A, mapped to UniProt Q13946. Sequence length is 482 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q13946
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 1016 compounds, and 148 assays for this target. The dominant activity type is IC50. CHEMBL3360172 is the current potency anchor at pChEMBL 9.5.
Use CHEMBL3360172 as the tractability anchor when discussing potency (pChEMBL 9.5).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 9.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why High affinity 3',5'-cyclic-AMP phosphodiesterase 7A matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13946, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1016
Total Compounds
148
Total Assays
2
Approved Drugs
IC50: 868.0, KI: 34.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3360172
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL3360170
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL4297384
|
9.1 | IC50 | — |
|
|
No preferred name
CHEMBL3354181
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL3360169
|
9.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CRISABOROLE
CHEMBL484785
|
2016 |
Source Header